Vascular BioSciences Named the 2015 Winner of the Buzz of Bio "Pipelines of Promise" Competition

Top Quote VBS Voted By Industry Peers Best Biotech Drug Pipeline of 2015. End Quote
  • Santa Barbara-Santa Maria-Goleta, CA (1888PressRelease) May 27, 2015 - The Biotech International Organization (BIO) announced Vascular BioSciences (VBS) as the winner of its Buzz of BIO competition in the "Pipelines of Promise" category. The contest is designed to recognize the most innovative biotech company with the most promising drug pipeline in the industry. The competition awards the winner with a featured company presentation as part of the BIO Business Forum as well as free participation in BIO One-on-One Partnering to source potential industry collaborations and funding opportunities.

    BIO, the world's largest international trade association, represents biotechnology companies, academic institutions, state biotechnology centers and related organizations from the United States and 30 other nations. The BIO International Convention, recognized as the largest global event for the biotechnology industry attracting the biggest and most influential names in biotech, offers key networking and partnering opportunities for companies and provides insight into major trends affecting the industry.

    Vascular BioSciences was selected by its industry peers in biotechnology as the winner in the "Pipelines of Promise" category for the company's innovative and exciting discoveries in developing first-in-class treatments for often fatal diseases. Our disease homing CARSKNKDC (CAR) peptide is currently being developed to improve sepsis survival, accelerate wound healing, ameliorate cancer cachexia and selectively increase the drug delivery of co-administered therapeutics in pulmonary hypertension and triple negative breast cancer. CAR, a cyclic peptide composed of 9 natural amino acids, selectively targets and penetrates diseased tissues by binding to heparan sulfate moieties expressed by cells in injured tissues.

    Vascular BioSciences CEO, David Mann commented, "I am honored that VBS has been recognized as having one of the best drug pipelines in the industry by our peers. I am excited to share the story and potential of our CAR peptide at this year's BIO Conference in Philadelphia."

    About Vascular BioSciences
    Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides targeted solutions for serious diseases in order to enhance and prolong human life.

    Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult-to-treat diseases.

    More information about our CAR peptide and VBS is available at

  • FB Icon Twitter Icon In-Icon
Contact Information